Prosecution Insights
Last updated: April 19, 2026

Shanghai Henlius Biotech Inc.

5 pending office actions

Portfolio Summary

5
Total Pending OAs
2
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
17905496 PHARMACEUTICAL FORMULATION COMPRISING BEVACIZUMAB SAOUD, CHRISTINE J 1645 Non-Final OA Sep 01, 2022
17822710 ANTI-CD137 CONSTRUCTS AND USES THEREOF SANG, HONG 1646 Non-Final OA Aug 26, 2022
17822737 ANTI-CD137 CONSTRUCTS, MULTISPECIFIC ANTIBODY AND USES THEREOF BRISTOL, LYNN ANNE 1643 Final Rejection Aug 26, 2022
17811455 ANTI-TIGIT ANTIBODIES AND METHODS OF USE HOPKINS, SAMANTHA LAKE 1641 Non-Final OA Jul 08, 2022
17758399 PROGRAMMED CELL DEATH RECEPTOR 1 ANTIBODY FORMULATION AND USE THEREOF CHEONG, CHEOM-GIL 1645 Final Rejection Jul 05, 2022

Managing Shanghai Henlius Biotech Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month